In 2018, Kinoshita et al. conducted a trial of trastuzumab monotherapy in ten pretreated HER2-positive lung adenocarcinoma patients (three with HER2 OE, and seven with HER2 MUT), observing no objective responses. Here, ERBB2 is linked to lung adenocarcinoma.